2024-10-18 - Analysis Report
## Amgen Inc. (AMGN) Stock Analysis

**Company Overview:** Amgen Inc. is a leading biotechnology company that develops and manufactures biopharmaceuticals.

**1. Performance Comparison:**

* **Cumulative Return:** AMGN has a cumulative return of 79.87% compared to the S&P 500 (VOO) with 136.93%.
* **Performance Gap:** AMGN is currently lagging behind the S&P 500 by -57.06% which represents 29.04% of the maximum historical gap.

**2. Recent Price Movements:**

* **Closing Price:** $321.63
* **5-day Moving Average:** $324.14
* **20-day Moving Average:** $323.98
* **60-day Moving Average:** $326.99

**3. Technical Indicators:**

* **RSI:** 52.84 (Neutral)
* **PPO:** 0.11 (Slight Bullish)
* **Delta_Previous_Relative_Divergence:** -14.28 (-): Suggests a potential short-term decline.
* **Expected Return:** 0.0% - The model currently predicts no outperformance compared to the S&P 500 within the next 5 years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-07 | 1.39 | 8.39 B$ |
| 2024-05-03 | -0.21 | 7.45 B$ |
| 2023-10-31 | 3.23 | 6.90 B$ |
| 2023-08-04 | 2.58 | 6.99 B$ |
| 2024-08-07 | 2.58 | 6.99 B$ |

* **Latest Earnings:** The most recent earnings report on 2024-08-07 showed an EPS of $1.39, exceeding analyst expectations. 
* **Revenue Growth:** Revenue is steadily increasing, suggesting a stable growth trajectory.

**5. News and Recent Issues:**

* **Market Outlook:** Recent market analysis suggests that AMGN's share price may be influenced by the success of its new product launches, particularly in the oncology segment. 
* **Analyst Opinions:** While AMGN is considered a stable, dividend-paying stock, analyst opinions are mixed. Some analysts remain bullish on the company's long-term potential, while others express concerns about the competitive landscape in the biopharmaceutical market.
* **Performance Highlights:** AMGN has shown consistent performance, with a strong dividend history and a robust pipeline of new drugs. However, recent regulatory scrutiny of the company's blockbuster drugs and potential competition from other biotech companies could pose challenges.

**6. Overall Analysis:**

AMGN is a well-established biotechnology company with a track record of solid performance. Recent earnings have been positive and revenue is growing steadily. However, the stock is currently lagging behind the S&P 500. While technical indicators suggest a potential short-term decline, analysts remain divided about its future prospects. Investors should closely monitor the impact of new product launches, regulatory developments, and competitive pressures on the company's growth trajectory.

**7. Report:**

Amgen Inc. (AMGN) is a leading biotechnology company that has seen consistent growth in recent years. However, the company's stock is currently lagging behind the S&P 500, with a cumulative return of 79.87% compared to the S&P 500's 136.93%. This performance gap represents 29.04% of the maximum historical gap. While recent earnings have been positive, exceeding analyst expectations, and revenue is growing steadily, technical indicators suggest a potential short-term decline. 

Analysts are divided about the future prospects of AMGN. Some remain bullish on the company's long-term potential, citing its strong dividend history, robust pipeline of new drugs, and focus on key therapeutic areas like oncology. Others express concerns about the competitive landscape in the biopharmaceutical market and regulatory scrutiny of the company's blockbuster drugs. 

Investors should closely monitor the impact of new product launches, regulatory developments, and competitive pressures on AMGN's growth trajectory. They should also consider the stock's current valuation relative to its peers and the broader market before making any investment decisions. 
